Evaluation of the Effect of Double Inhibition of Angiotensin II AT1 Receptor and Neprilysin Activity on Sympathic Nervous System Activity in Patient With Heart Failure

Trial Profile

Evaluation of the Effect of Double Inhibition of Angiotensin II AT1 Receptor and Neprilysin Activity on Sympathic Nervous System Activity in Patient With Heart Failure

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Heart failure
  • Focus Pharmacodynamics
  • Acronyms B2AN-SNS
  • Most Recent Events

    • 25 Oct 2017 Planned End Date changed from 1 Nov 2017 to 1 May 2019.
    • 25 Oct 2017 Planned primary completion date changed from 1 Nov 2017 to 1 May 2019.
    • 17 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top